Impact of radiotherapy on survival in resected or unresectable anaplastic thyroid carcinomas, a Rare Cancer Network study.

Anaplastic thyroid carcinoma Carcinome thyroïdien anaplasique Prognosis Pronostic Radiotherapy Radiothérapie Risk score model Survie Survival

Journal

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
ISSN: 1769-6658
Titre abrégé: Cancer Radiother
Pays: France
ID NLM: 9711272

Informations de publication

Date de publication:
Sep 2022
Historique:
received: 04 10 2021
revised: 04 01 2022
accepted: 14 01 2022
pubmed: 18 6 2022
medline: 17 8 2022
entrez: 17 6 2022
Statut: ppublish

Résumé

Anaplastic thyroid carcinomas (ATC) are a heterogenous group of tumors of overall dismal prognosis. We designed models to identify relevant prognostic factors of survival of irradiated ATC patients including radiotherapy modalities (field size, dose). Between 2000 and 2017, 166 ATC patients' treatments were divided into surgery and postoperative radiotherapy (poRT) or definitive radiotherapy (RT). Multiple imputation approach was used for missing data. Prognostic factors were identified using Lasso-penalized Cox modelling and predicted risk scores were built. Patients undergoing RT (n=70) had more adverse patient and disease characteristics than those undergoing poRT (n=96). Corresponding median survival rates were 5.4 and 12.1 months, respectively. PoRT patients undergoing poRT more likely received extended-field radiotherapy with prophylactic nodal irradiation, but rather received platinum- vs. adriamycin-based chemoradiotherapy. Radiotherapy was conventionally fractionated, delivered >60Gy in 51.9% and 61.7% and used extended fields in 88.5% and 71.2% of patients with poRT or RT. Radiotherapy interruption rates for toxicity were similar in the two groups. The best poRT-group model identified age>45yo, PS≥1, pathologic tumor stage≥pT4b,>N1 and R2 resection as poor prognostic factors. The best RT-group model (C-index of 0.72) identified PS≥3,>N1 and extended-field radiotherapy with prophylactic nodal irradiation (as opposed to tumour-bed irradiation only) as poor prognostic factors. In patients undergoing poRT, radiotherapy parameters had little influence over their survival irrespective of patient, disease characteristics, and quality of resection. In patients undergoing RT, extended-field radiotherapy improved survival in addition to PS and nodal stage.

Identifiants

pubmed: 35715353
pii: S1278-3218(22)00041-5
doi: 10.1016/j.canrad.2022.01.003
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

717-723

Informations de copyright

Copyright © 2022. Published by Elsevier Masson SAS.

Auteurs

X S Sun (XS)

Department of Radiation Therapy, University Hospital Besancon-Montbeliard, Montbeliard, France. Electronic address: sun.xushan@wanadoo.fr.

J Le Guevelou (J)

Department of Radiation Oncology, Centre François Baclesse, Caen, France.

J Jacquemin (J)

Département Prévention et Santé Publique, Centre Léon Bérard, Lyon, France.

Y Drouet (Y)

Département Prévention et Santé Publique, Centre Léon Bérard, Lyon, France.

T S Sio (TS)

Department of Radiation Oncology, Mayo Clinic, Phoenix, Arizona, USA.

G Bar-Sela (G)

Department of Radiation Oncology, Rambam health Care Campus, Haifa, Israel.

C Carrie (C)

Department of Radiation Oncology, Centre Leon Berard, Lyon, France.

J-C Faivre (JC)

Department of Radiation Oncology, Institut de Cancérologie de Lorraine, Nancy, France.

J Khalifa (J)

Department of Radiation Oncology, Oncopole, Toulouse, France.

C Demiroz (C)

Department of Radiation Oncology, Uludag University school of medicine, Bursa, Turkey.

H Qiu (H)

Department of Radiation Oncology, University Hospital, Limoges, France.

U Schick (U)

Department of Radiation Oncology, CHRU Brest, Brest, France.

B Atalar (B)

Department of Radiation Oncology, University Hospital Acibadem MAA University, School of Medicine, Istanbul, Turkey.

N Fakhry (N)

Department of Surgery, CHU La Conception, Marseille, France.

L Mengue (L)

Department of Radiation Therapy, University Hospital Besancon-Montbeliard, Montbeliard, France.

J Pan (J)

Department of Radiation Oncology, Fujian Province Tumor Hospital, Fuzhou, China.

S Servagi-Vernat (S)

Department of Radiation Oncology, Institut Jean Godinot, Reims, France.

J Thariat (J)

Department of Radiation Oncology, Centre François Baclesse, Caen, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH